Evidence map›Paper›PMID 34395710›Full record

ArticleOpen forum infectious diseases2021

Association of Physician Orders for Life-Sustaining Treatment With Inpatient Antimicrobial Use at End of Life in Patients With Cancer.

Olivia S Kates, Elizabeth M Krantz, Juhye Lee, John Klaassen, Jessica Morris, Irina Mezheritsky, Ania Sweet, Frank Tverdek, Elizabeth T Loggers, Steven A Pergam and 1 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olivia S KatesDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-4381-0049
Elizabeth M KrantzVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Juhye LeeDepartment of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
John KlaassenSeattle Cancer Care Alliance, Seattle, Washington, USA.
Jessica MorrisVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Irina MezheritskySeattle Cancer Care Alliance, Seattle, Washington, USA.
Ania SweetVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Frank TverdekVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Elizabeth T LoggersSeattle Cancer Care Alliance, Seattle, Washington, USA.
Steven A PergamDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Catherine LiuDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-7532-4822

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Training Program in Infectious Diseases in the Immunocompromised HostT32AI118690 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2016 to 2025
$4.0M
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant RecipientsU01AI132004 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HALASA, NATASHA BASSAM · 2017 to 2019
$2.7M
NCI NIH HHS P30 CA015704NIAID NIH HHS T32 AI118690NIAID NIH HHS U01 AI132004
6 · The paper itself

Abstract

backgroundAntimicrobial utilization at end of life is common, but whether advance directives correlate with usage is unknown. We sought to determine whether Washington State Physician Orders for Life Sustaining Treatment (POLST) form completion or antimicrobial preferences documented therein correlate with subsequent inpatient antimicrobial prescribing at end of life.

methodsThis was a single-center, retrospective cohort study of adult patients at a cancer center who died between January 1, 2016, and June 30, 2019. We used negative binomial models adjusted for age, sex, and malignancy type to test the relationship between POLST form completion ≥30 days before death, antimicrobial preferences, and antimicrobial days of therapy (DOT) per 1000 inpatient-days in the last 30 days of life.

resultsAmong 1295 eligible decedents with ≥1 inpatient-day during the last 30 days of life, 318 (24.6%) completed a POLST form. Of 318, 120 (37.7%) were completed ≥30 days before death, 35/120 (29.2%) specified limited antimicrobials, 55/120 (45.8%) specified full antimicrobial use, and 30/120 (25%) omitted antimicrobial preference. Eighty-three percent (1070/1295) received ≥1 inpatient antimicrobial. The median total and intravenous (IV) antimicrobial DOT/1000 inpatient-days were 1077 and 667. Patients specifying limited antimicrobials had significantly lower total antimicrobial DOT (adjusted incidence rate ratio [IRR], 0.68; 95% CI, 0.49-0.95;

conclusionsIndicating a preference for limited antimicrobials on a POLST form ≥30 days before death may lead to less inpatient antimicrobial use in the last 30 days of life.

Indexed as

advance directivesantimicrobial stewardshipcancerend-of-life careoncology

Identifiers

PMID34395710
PMCPMC8360239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.